Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS ...

The US Food and Drug Administration FDA has approved Symbravo, an oral combination of meloxicam and rizatriptan, for the ...

Meloxicam is a nonsteroidal, anti-inflammatory molecule developed with Axsome’s Molecular Solubility Enhanced Inclusion ...

Mizuho analyst Graig Suvannavejh raised the firm’s price target on Axsome Therapeutics (AXSM) to $137 from $122 and keeps an Outperform rating ...

The Food and Drug Administration (FDA) has approved Symbravo ® (meloxicam/rizatriptan) for the acute treatment of migraine with or without aura in adults.

The FDA approves AXSM's Symbravo for the acute treatment of migraine with or without aura in adults. The latest nod diversifies its commercial portfolio.

FDA approves Symbravo for acute migraine relief, combining rizatriptan and meloxicam. Discover its unique benefits and fast absorption for effective symptom control.

Truist Securities adjusted their financial outlook for Axsome Therapeutics (NASDAQ:AXSM), increasing the price target to $190 from the previous $180 while maintaining a Buy rating on the company's ...

Axsome Therapeutics (AXSM) will host a virtual investor event and conference call at 8:00 AM Eastern Time to discuss the U.S. Food and Drug ...

The Axsome management team will provide an overview of SYMBRAVO and anticipated commercial plans. The presenters will be available to answer questions at the end of the presentation. To access the ...